Exhibitor

Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies that address significant unmet medical need in the treatment of cardiopulmonary diseases. Bellerophon's pipeline programs are researching 3 potential indications with INOpulse, a delivery system for inhaled nitric oxide (NO) for Pulmonary Arterial Hypertension (PAH), Pulmonary Hypertension in Interstitial Lung Disease (PH-ILD) and Pulmonary Hypertension associated with Chronic Obstructive Pulmonary Disease (PH-COPD).